The purpose of this study is to evaluate the safety, tolerability and drug levels of BMS-986446 in healthy participants including healthy participants of Japanese ethnicity.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
24
Specified dose on specified days
Specified dose on specified days
Local Institution - 0001
Cypress, California, United States
Incidence of adverse events (AEs)
Time frame: Up to Day 85
Number of participants with vital sign abnormalities
Time frame: Up to Day 85
Number of participants with electrocardiogram (ECG) abnormalities
Time frame: Up to Day 85
Number of participants with physical examination abnormalities
Time frame: Up to Day 85
Number of participants with body weight abnormalities
Time frame: Up to Day 85
Number of participants with clinical laboratory abnormalities
Time frame: Up to Day 85
Maximum observed plasma concentration (Cmax)
Time frame: Up to Day 85
Time of maximum observed plasma concentration (Tmax)
Time frame: Up to Day 85
Area under concentration time curve from time 0 to time of last quantifiable concentration [AUC(0-T)]
Time frame: Up to Day 85
Number of participants with anti-drug antibody (ADA)
Time frame: Up to Day 85
Geometric mean ratios of Cmax
Time frame: Up to Day 85
Geometric mean ratios of [AUC(0-T)]
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Up to Day 85
Geometric mean ratios of area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]
Time frame: Up to Day 85